BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 17023095)

  • 41. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
    French N; Moore M; Haikala R; Kayhty H; Gilks CF
    J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.
    Bliss SJ; O'Brien KL; Janoff EN; Cotton MF; Musoke P; Coovadia H; Levine OS
    Lancet Infect Dis; 2008 Jan; 8(1):67-80. PubMed ID: 17974480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
    Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
    Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
    Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
    Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood.
    Salt P; Banner C; Oh S; Yu LM; Lewis S; Pan D; Griffiths D; Ferry B; Pollard A
    Clin Vaccine Immunol; 2007 May; 14(5):593-9. PubMed ID: 17344347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.
    Madhi SA; Kuwanda L; Cutland C; Klugman KP
    Clin Infect Dis; 2005 May; 40(10):1511-8. PubMed ID: 15844075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
    Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
    JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
    Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
    Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
    Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
    Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine.
    Bogaert D; Sluijter M; De Groot R; Hermans PW
    Vaccine; 2004 Sep; 22(29-30):4014-20. PubMed ID: 15364451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine.
    Aguiar SI; Serrano I; Pinto FR; Melo-Cristino J; Ramirez M;
    Clin Microbiol Infect; 2008 Sep; 14(9):835-43. PubMed ID: 18844684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.